Zydus Launches Relugolix, a Breakthrough Prostate Cancer Therapy, at 50% Lower Cost in India

30 Jan 2024 , 01:03 PM

Zydus Lifesciences shares surged in morning trade following the launch of the Relugolix drug for cancer patients in India.

Relugolix, marketed under the brand name Rexigo, offers a once-a-day therapy for suppressing testosterone in patients with advanced prostate cancer, making it the first of its kind in India.

The drug has been in use in developed countries for the past four years but was previously unavailable to patients in India.

Zydus Lifesciences aims to ensure accessibility and affordability with the pricing of Relugolix at ₹6,995 per month, representing a 50% reduction compared to existing injectable options.

The introduction of Relugolix marks a significant advancement in prostate cancer management, providing patients and doctors with a new option characterized by convenience, safety, and rapid efficacy.

Prostate cancer is one of the leading cancers in men, with over 43,000 cases registered in India in 2022, according to the National Cancer Registry Programme.

Prostate cancer progression is primarily driven by testosterone, necessitating Androgen Deprivation Therapy (ADT) to lower testosterone levels, either through surgery or medication.

Current medications for prostate cancer treatment are injectables administered via various routes, requiring supervision by a caregiver.

Zydus Lifesciences, a leading player in the Indian oncology segment, has a track record of pioneering first-in-India biosimilars and therapies.

With a patient-centric approach and specialized expertise, Zydus is committed to improving access and affordability in cancer treatments, with six out of eight oncology pillar brands leading their respective categories.

For feedback and suggestions, write to us at [e-mail]